— Adds RiverVest Venture Partners, Qatar Investment Authority and Redmile Group to List of Financial Backers — Proceeds Will Advance Growing Portfolio of Therapeutic Candidates for Various Cancers SEATTLE, Washington – September 11, 2018 – OncoResponse, an immunotherapy company developing a portfolio of novel antibodies to high-value targets for the treatment of cancer, today announced the […]
SAN CARLOS, Calif., July 24, 2018 (GLOBE NEWSWIRE) — Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of various eosinophil and mast cell related diseases, today announced the closing of its initial public offering of 8,203,332 shares of its common stock, sold by the Company at […]
SAN CARLOS, Calif., July 19, 2018 (GLOBE NEWSWIRE) — Allakos Inc., (Nasdaq:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of various eosinophil and mast cell related diseases, today announced the pricing of its initial public offering of 7,133,333 shares of its common stock at a public offering price […]
(Cincinnati, OH– April 18, 2018) Standard Bariatrics, Inc., an innovator of bariatric surgical devices, has raised a Series A round of financing.
Represents 9th Exit from RiverVest Venture Fund II ST. LOUIS and CLEVELAND (April 3, 2018) – RiverVest Venture Partners today announced portfolio company Securus Medical Group, Inc., has been sold to Boston Scientific Corporation (NYSE: BSX). Boston Scientific has been an investor in Securus since 2016, and the transaction price for the remaining stake not […]
Acquisition strengthens electrophysiology cardiac ablation portfolio with thermal monitor MARLBOROUGH, Mass., April 3, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the acquisition of Securus Medical Group, Inc., a privately-held company that has developed a thermal monitoring system for the continuous measurement of esophageal temperature. Boston Scientific has been an investor in Securus […]
SOUTH SAN FRANCISCO, March 5, 2018 — Lyric Pharmaceuticals, Inc. (Lyric), a biopharmaceutical company, today announced the completion of enrollment of PROMOTE, an international, multicenter, randomized, controlled Phase 2 study of LP101 (ulimorelin) for the treatment of enteral feeding intolerance (EFI) in critically ill patients.
DURHAM, N.C.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced that the company has appointed Carl J. St. Bernard as president and chief executive officer.
— Proceeds will support advancement of AK002 in five disease areas — — Lead clinical program evaluating AK002 in eosinophilic gastroenteritis, an inflammatory gastrointestinal disease — SAN CARLOS, Calif., December 13, 2017– Allakos Inc., a private, clinical-stage biopharmaceutical company focused on the development of antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced […]
Spruce Biosciences Receives FDA Orphan Drug Designation for SPR001 for the Treatment of Congenital Adrenal Hyperplasia Clinical-stage biotech granted orphan drug designation for the treatment of CAH, a rare endocrine disease San Francisco – December 4, 2017 – Spruce Biosciences, a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders, today announced that the U.S. Food […]
ST. LOUIS, MO (Oct. 25, 2017)—RiverVest Venture Partners announced today that Ronald T. Borchardt, Ph.D. and Jared Rutter, Ph.D. have joined the life science venture capital firm’s Scientific Advisory Board. Comprised of leaders in medical research, RiverVest’s Scientific Advisory Board provides expert guidance to the venture firm as it identifies and invests in promising biopharmaceutical […]
Clinical-stage, rare endocrine disease Company expands leadership team and advances lead candidate for congenital adrenal hyperplasia San Francisco – October 12, 2017 – Spruce Biosciences, a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders, today provided a corporate update, building upon a previously closed Series A financing of $20 million to expand its […]